IKT · Inhibikase Therapeutics Inc
United States · RS rating 22 · As of 2026-11-03
| Price | 1.48 USD |
|---|---|
| 1-day change | -3.9% |
| RS rating (overall / 1M / 3M / 12M) | 22 / 15 / 14 / 51 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 27 / 22 / 33 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -10.0% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +41.3% |
| Market cap (USD) | $254.8M |